Fox Chase Cancer Center 333 Cottman Avenue, Philadelphia, PA 19111
Education:
Medical School Mount Sinai School of Medicine Graduated: 1977 Medical School Fletcher Allen Health Care Graduated: 1977 Medical School New England Med Center Hosps Graduated: 1977
Lombardi Comprehensive Cancer Center 3800 Reservoir Rd NW STE E501, Washington, DC 20007 202 444-2198 (phone), 202 444-7797 (fax)
Education:
Medical School Mount Sinai School of Medicine Graduated: 1977
Conditions:
Pancreatic Cancer
Languages:
English Spanish
Description:
Dr. Weiner graduated from the Mount Sinai School of Medicine in 1977. He works in Washington, DC and specializes in Medical Oncology. Dr. Weiner is affiliated with Medstar Georgetown University Hospital.
Resumes
Vice President, Business Development, Pharmaceutical Softgel, North America
Catalent Pharma Solutions Jul 2015 - Aug 2017
Director of Business Development , North America Softgel
Catalent Pharma Solutions Jul 2015 - Aug 2017
Vice President, Business Development, Pharmaceutical Softgel, North America
Catalent Pharma Solutions Oct 2013 - Jul 2015
Regional Sales Manager, Pharmaceutical Softgel
Catalent Pharma Solutions Jul 2012 - Sep 2013
Account Director, Pharmaceutical Softgel Us
A+ Secure Packaging, Llc Jan 2011 - Jul 2012
Vice President of Sales
Education:
Saint Joseph's University 1992 - 1997
Master of Business Administration, Masters, Management
Rutgers University 1976 - 1981
Bachelors, Bachelor of Science, Chemistry
Pennsauken High School
Skills:
Pharmaceutical Industry Product Development Cross Functional Team Leadership Business Development Gmp Management New Business Development Leadership Fda Project Management Packaging Strategic Planning Medical Devices Negotiation Manufacturing Account Management Sales Competitive Analysis Quality System Lean Manufacturing Pharmaceutics Product Launch Contract Negotiation Process Improvement Biotechnology Six Sigma Supply Chain Continuous Improvement Technology Transfer Customer Service Validation Strategy Forecasting Key Account Management Sop Cro Team Building Operations Management Business Strategy Regulatory Affairs Team Leadership Budgets Change Management Marketing Strategy Sales Operations Project Planning Mentoring Customer Relations Budgeting Pharmaceuticals
Gregory P. Adams - Hatboro PA, US Eva M. Horak - West Orange NJ, US Louis M. Weiner - Philadelphia PA, US James D. Marks - Kensington CA, US
Assignee:
The Regents of the University of California - Oakland CA Fox Chase Cancer Center - Philadelphia PA
International Classification:
C07K 16/00
US Classification:
5303877, 4241301, 4241361, 4241381
Abstract:
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
Anti-Egfr Family Antibodies, Bispecific Anti-Egfr Family Antibodies And Methods Of Use Thereof
Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.
Bispecific Single Chain Fv Antibody Molecules And Methods Of Use Thereof
Gregory Adams - Hatboro PA, US Eva Horak - Philadelphia PA, US Louis Weiner - Philadelphia PA, US James Marks - Kensington PA, US
International Classification:
A61K039/395 C07K016/28
US Classification:
424/143100, 530/388250, 530/388220
Abstract:
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
Bispecific Single Chain Fv Antibody Molecules And Methods Of Use Thereof
Gregory Adams - Hatboro PA, US Eva Horak - West Orange NJ, US Louis Weiner - Philadelphia PA, US James Marks - Kensington CA, US
International Classification:
A61K 39/395 C07K 16/44 C07K 16/28
US Classification:
424133100, 424143100, 530387300, 530388220
Abstract:
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
Egfr/Nedd9/Tgf-Beta Interactome And Methods Of Use Thereof For The Identification Of Agents Having Efficacy In The Treatment Of Hyperproliferative Disorders
Hossein Borghaei - King of Prussia PA, US Louis M. Weiner - Washington DC, US
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
C07K 16/30 A61P 35/00 A61K 39/395
US Classification:
4241351, 5303877, 5303873, 5303913, 4241781
Abstract:
Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.
Egfr/Nedd9/Tgf-Beta Interactome And Methods Of Use Thereof For The Identification Of Agents Having Efficacy In The Treatment Of Hyperproliferative Disorders
"These studies are showing there may be a path forward in solid tumors" with CAR-T therapies, said Dr. Louis Weiner, director of the Georgetown Lombardi Comprehensive Cancer Center and one of the conference leaders. It may hold promise for some cancers of the stomach, breast, colon, lung and other a
Date: Mar 31, 2019
Category: Health
Source: Google
Immune System Drugs Melt Tumors, Leading A Cancer Revolution
We are in the middle of a revolution, said Louis Weiner, of Georgetown University, at an AACR press conference about the immunotherapies. I dont think that is hyperbolic. Those are the kinds of observations that weve rarely seen in our business. What really makes it exciting is that it is not j
stimated that over 10 years, biosimilars will save up to $44 billion. As noticed by Louis Weiner, director of the Lombardi Comprehensive Cancer Center and head of the department of oncology at Georgetown University, the use of Neupogen has mostly been reduced because of the price. Thats why the aut
Date: Mar 07, 2015
Source: Google
Approval of Merck-developed melanoma drug Keytruda by FDA is a big step
"This is not a drug that attacks the cancer directly. It enables the immune system to do the job that it is capable of doing," said Louis Weiner, from Georgetown University's Lombardi Comprehensive Cancer Center. "This is the first beachhead that's been taken. It's going to be all out assault on man
Date: Sep 05, 2014
Category: Health
Source: Google
One-two vaccine punch against ovarian cancer takes center stage at AACR
Louis Weiner, MD, of Georgetown University, who was not part of the study, told reporters that the promising combination therapy promised a more effective way to treat aggressive cancers. That said, a small study like this can only offer a glimpse of a therapy's efficacy and safety, demanding furthe
Date: Apr 08, 2013
Category: Health
Source: Google
Research Shows Promise in Using Immune Therapy on Ovarian Cancer
"It's now possible to devise very efficient and complex but feasible combination strategies [starting with] a vaccination that will basically point the immune system in the direction of the tumor," said Louis Weiner, M.D. from Georgetown University. Weiner was not a part of the study. "And then you
The study "shows that it's now possible to devise very efficient and complex but feasible combination strategies (starting with) a vaccination that will basically point the immune system in the direction of the tumor," commented Louis Weiner, MD, of Georgetown University here, who was not part of th
Acting as a discussant for the studies, Louis Weiner, MD, said the findings suggest that therapies for HER2-positive breast cancer have become so effective as to render biomarkers irrelevant in some cases.